0455 (0455) Fair Value & Analysis

Healthcare · Market cap HK$185M

0 0455 0455 · HK

PriceHK$0.0860

Fair ValueHK$0.0378

Upside-56.0%

Quality42/100

Evidence: Medium Range HK$0.0292 – HK$0.0464

Fair value as of: Jul 2, 2026

From 8 valuation models · updated today

Price vs Fair Value (12 months)

12‑month range HK$0.0850 – HK$0.1920 · fair‑value band HK$0.0292 – HK$0.0464 · the HK$0.0860 price screens above the HK$0.0378 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0455 (0455) currently trades at HK$0.0860, while our model-based Fair Value estimate is HK$0.0378 — implying the stock looks roughly 56.0% overvalued today. We read business quality at 42/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, 0455 generated revenue of HK$323M at a net margin of -21.7%. Revenue grew 7.2% year over year. It earns a return on equity of -14.6%. Net debt stands at HK$67.9M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$323M

Revenue growth (YoY) +7.2%

Net margin -21.7%

Return on equity -14.6%

Free cash flow HK$2.8M FY2026

Operating margin -11.0%

More key figures

EPS (TTM) HK$-0.0200

EPS growth (YoY) +244%

Net debt HK$67.9M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

0455 reported revenue of HK$323M in FY2026 versus HK$510M in FY2022, a compound −10.8%/yr. Reported net income was −HK$70.0M in FY2026.

Revenue −10.8%/yr

FY22 HK$510M

FY23 HK$547M

FY24 HK$532M

FY25 HK$330M

FY26 HK$323M

Net income

FY22 −HK$21.7M

FY23 −HK$54.6M

FY24 −HK$24.2M

FY25 −HK$61.4M

FY26 −HK$70.0M

Is 0455 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥49.36	¥30.99	-37%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$24.45	R$6.33	-74%
Hansoh Pharmaceutical Group 3692	HK$29.32	HK$23.94	-18%
Divi's Laboratories Limited DIVISLAB	₹6,623	₹1,461	-78%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0455 (0455) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.0378 versus a price of HK$0.0860 — about −56% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 0455?

Our model-based fair value for 0455 is HK$0.0378 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.0860.

What is the quality score of 0455?

0455 has a Quality Score of 42/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0455 (0455)?

0455 reported trailing-twelve-month revenue of about HK$323M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 0455?

The net profit margin of 0455 is about -21.7%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.